 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered into a definitive agreement with ten accredited investors in a private placement of 30 million of DiaMedicas common shares at a purchase price of 3.92 per share, equal to the per share closing price of the Companys common shares on September 24, 2021. The Comp 